Provided by Tiger Trade Technology Pte. Ltd.

Palisade Bio Inc.

1.51
+0.06004.14%
Volume:480.55K
Turnover:719.82K
Market Cap:262.74M
PE:-7.49
High:1.52
Open:1.49
Low:1.47
Close:1.45
52wk High:2.86
52wk Low:1.32
Shares:174.00M
Float Shares:130.00M
Volume Ratio:0.91
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2015
EPS(LYR):-0.3014
ROE:-51.37%
ROA:-32.98%
PB:2.16
PE(LYR):-5.01

Loading ...

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pali-2108 into Phase 2 Development

THOMSON REUTERS
·
Aug 11

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

GlobeNewswire
·
Aug 11

Palisade Bio Inc Expected to Post a Loss of 5 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Palisade Bio Inc : Oppenheimer Initiates Coverage with Outperform Rating; Target Price $8

THOMSON REUTERS
·
Jul 23

Insider Power Move: Palisade Bio Director Makes Bold New Share Grab

TIPRANKS
·
Jul 11

Palisade Bio Director Robert Baltera Jr Acquires USD 88,687.50 in Common Shares

Reuters
·
Jul 11

Palisade Bio to Meet Investors at Leerink Partners Therapeutics Forum July 14-15

Reuters
·
Jul 10

Palisade Bio Director Robert Baltera Jr. Acquires USD 101,044 of Common Shares

Reuters
·
Jul 09

Palisade Bio Director Robert Baltera Jr Acquires USD 59,400 in Common Shares

Reuters
·
Jul 07

Analysts Are Bullish on Top Healthcare Stocks: Coya Therapeutics, Inc. (COYA), Palisade Bio (PALI)

TIPRANKS
·
Jul 06

Palisade Bio Wins FDA IND Clearance for Pali-2108 Ulcerative Colitis Trial

Reuters
·
Jun 29

Palisade Bio - Ascentra-uc Enrollment Expected H2 2026; Primary Efficacy Results Expected H2 2027

THOMSON REUTERS
·
Jun 29

Palisade Bio - Expects to Submit Ind for Ascentra-cd in Crohn's Disease in H2 2026

THOMSON REUTERS
·
Jun 29

Palisade Bio Receives FDA Clearance of Ind for Pali-2108 and Plans to Initiate Global Phase 2 Ascentra-uc Study in Ulcerative Colitis

THOMSON REUTERS
·
Jun 29

Palisade Bio - Ascentra-uc Phase 2 Trial to Enroll up to 204 Patients in North America and Europe

THOMSON REUTERS
·
Jun 29

Palisade Bio director Robert Baltera Jr. files initial beneficial ownership statement

Reuters
·
Jun 19

Palisade Bio director Jordan Michael Zwick files initial beneficial ownership statement (Form 3)

Reuters
·
Jun 13

Palisade Bio raises authorized common shares to 450 million from 300 million

Reuters
·
Jun 12

Palisade Bio adds Robert Baltera, Jordan Zwick to board of directors

Reuters
·
Jun 11

Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium

GlobeNewswire
·
Jun 09